FYC: High Risk, Questionable Reward Amid Tech Softness And Inflation Concerns

Celcuity: Stronger Clinical Evidence, Much Lower Valuation

Strong Earnings Aren’t Strong Enough for the AI Era

Strong quarters are not enough in the era of heavy AI capital expenditures. Investors want proof all the spending pays o…

Ichor Holdings: The Sell-Off Looks Overdone As Margins Improve